Endocrine Abstracts

Introduction: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is tightly associated with type 2 diabetes (T2DM), the principal risk factor for disease progression, liver failure and cardiovascular complications. At present there are no licensed therapies and management aims to optimise metabolic risk factors through weight loss, and pharmacological interventions for diabetes and cardiovascular disease. A multidisciplinary approa...